CyberKnife-based prostate cancer patient radioablation - early results of irradiation in 200 patients

INTRODUCTION - Prostrate cancer (PC) is one of the most common malignancies and is frequently treated with an 8-week course of radiotherapy. CyberKnife (CK) based radioablation enables completion of therapy within 5-9 days.

The aim of this study is an evaluation of the effectiveness and tolerance of CyberKnife-based radioablation in prostate cancer patients.

MATERIALS AND METHODS - 200 PC patients (94 low risk [LR], 106 intermediate risk [IR]) underwent CK irradiation every other day (fraction dose [fd] 7. 25 Gy, total dose [TD] 36. 25 Gy, time 9 days). PSA varied from 1. 1 to 19. 5 (median 7. 7) and T stage from T1c to T2c. The percentage of patients with Androgen Deprivation Therapy (ADT), GI (gastrointestinal) and GU (genitourinary) toxicity (EORTC/RTOG scale), and PSA were checked at 1, 4 and 8 months, and thereafter every 6 months - up to a total of 26 months - post-treatment.

RESULTS - The percentage of patients without ADT increased from 47. 5% to 94. 1% after 26 months. The maximum percentage of acute G3 adverse effects was 0. 6% for GI, 1% for GU and G2 - 2. 1% for GI and 8. 5% for GU. No late G3 toxicity was observed. The maximum percentage of late G2 toxicity was 0. 7% for GI and 3. 4% for GU. Median PSA decreased from 7. 7 to 0. 1 ng/ml during FU. One patient relapsed and was treated with salvage brachytherapy.

CONCLUSIONS - We conclude that CK-based radioablation in low and intermediate risk PC patients is an effective treatment modality enabling OTT reduction and presents a very low percentage of adverse effects.

Central European journal of urology. 2015 Oct 15 [Epub]

Leszek Miszczyk, Aleksandra Napieralska, Agnieszka Namysł-Kaletka, Grzegorz Głowacki, Kinga Grabińska, Grzegorz Woźniak, Małgorzata Stąpór-Fudzińska

M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe